Company
Headquarters: Long Hanborough, United Kingdom
Employees: 33
CEO: Mr. Ahmad Ali Mortazavi
£65.7 Million
GBP as of Jan. 1, 2024
US$83.6 Million
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $622.07 B |
Vertex Pharmaceuticals Incorporated | $113.24 B |
CSL Limited | $95.75 B |
Regeneron Pharmaceuticals, Inc. | $76.33 B |
Marinomed Biotech AG | $56.13 B |
Company | Market Cap (USD) |
---|---|
Lilly | $689.42 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $487.54 B |
Johnson & Johnson | $353.05 B |
AbbVie | $301.60 B |
e-Therapeutics plc operates as a drug discovery company in the United Kingdom. The company's Network-Driven Drug Discovery platform perform in silico phenotypic screens to generate sets of small molecules that are enriched in active compounds ensuring high in vitro hit rates in complex phenotypic screens; and Genome-Associated Interaction Networks platform to analyze genome-wide association study data, which identifies disease variants at the genome level to identify potential intervention strategies, therapies, and diagnostics, as well as developing RNAi platform to modulate any gene to harness novel targets identified computationally. It also develops search engine technology. The company was founded in 2001 and is based in Long Hanborough, the United Kingdom.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Last Financial Reports Date | July 31, 2023 |
Revenue TTM | £340,000 |
EBITDA | £-12,558,000 |
Gross Profit TTM | £475,000 |
Profit Margin | 100.00% |
Operating Margin | -4356.25% |
Quarterly Revenue Growth | -45.80% |
e-therapeutics plc has the following listings and related stock indices.
Stock: LSE: ETX wb_incandescent
Stock: OTC: ETXPF wb_incandescent